Sökning: "Transthyretin Amyloidosis"
Visar resultat 16 - 20 av 30 avhandlingar innehållade orden Transthyretin Amyloidosis.
16. Familial amyloidosis with polyneuropathy : studies of genetic factors modifying the phenotype of the disease
Sammanfattning : Background. Familial Amyloidosis with Polyneuropathy (FAP) is an autosomal dominantly inherited systemic amyloid disease. The disease is caused by mutations in the transthyretin (TTR) gene, where close to 100 different amyloidogenic mutations have been identified. LÄS MER
17. Studies on molecular aspects of Transthyretin Amyloidosis
Sammanfattning : Proteins are versatile molecules that play a variety of roles in maintaining the human body, e.g. transport of nutrients. Transthyretin (TTR) is a 55 kDa homotetrameric protein found in human plasma and in the cerebrospinal fluid, responsible for the transport of retinol (vitamin A) and T4 (thyroxine). LÄS MER
18. Kinetic stabilization of transthyretin and its role as an inhibitor of Aβ amyloid formation
Sammanfattning : Amyloid formation occurs when normally soluble proteins and peptides misfold and aggregate into intractable threadlike structures called fibrils. There are currently more than 30 proteins associated with this aberrant structure, including the Aβ peptide in Alzheimer’s disease (AD) and transthyretin (TTR) in TTR amyloidosis. LÄS MER
19. Transthyretin in senile systemic amyloidosis and familial amyloidotic polyneuropathy
Sammanfattning : The amyloidoses comprise a heterogeneous group of disorders characterized by the deposition of fibrillar, proteinaceous amyloid deposits in various organs and tissues. To date, 17 different proteins of various sizes have been identified as amyloid proteins. LÄS MER
20. Targeting cytotoxic species in amyloid diseases
Sammanfattning : Amyloid diseases are a world-wide problem causing great human suffer and large economical costs. Although amyloid deposits, a common denominator in all amyloid disorders, are detrimental to the surrounding tissue, there is a poor correlation between total amyloid burden and clinical symptoms. LÄS MER